Celsion Corporation to Present at the H.C. Wainwright 24th Annual Global Investment Conference
Celsion Corporation (NASDAQ: CLSN) announced that CEO Dr. Corinne Le Goff will present at the H.C. Wainwright 24th Annual Global Investment Conference, held from September 12-14, 2022. Dr. Le Goff's presentation is scheduled for September 13 at 4:00 PM ET at the Lotte New York Palace Hotel. Investors can access a replay of the presentation on the company's website. Celsion is a clinical-stage biotechnology firm focused on innovative cancer treatments, including DNA-based immunotherapies like GEN-1 for ovarian cancer. For further details, visit www.celsion.com.
- None.
- None.
LAWRENCEVILLE, N.J., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage drug development company today announced that Dr. Corinne Le Goff, President and Chief Executive Officer will present a company overview and be available for 1x1 meetings at the upcoming H.C. Wainwright 24th Annual Global Investment Conference. The hybrid conference will be held from September 12-14 with in-person participation held at the Lotte New York Palace Hotel.
Dr. Le Goff will present in person on Tuesday, September 13th at 4:00 pm ET. A replay of the presentation will available under “Financial Events” in the Investors section of the Company’s website at: https://investor.celsion.com/financial-events.
About Celsion Corporation
Celsion is a fully integrated, clinical-stage biotechnology company focused on advancing a portfolio of innovative cancer treatments, including immunotherapies and DNA-based therapies, and a platform for the development of nucleic acid vaccines currently focused on SARS-CoV-2. The company’s product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer. Celsion also has two feasibility-stage platform technologies for the development of novel nucleic acid-based immunotherapies and other anticancer DNA or RNA therapies. Both are novel synthetic, non-viral vectors with demonstrated capability in nucleic acid cellular transfection. For more information on Celsion, visit www.celsion.com.
Forward-Looking Statements
Celsion wishes to inform readers that forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Readers are cautioned that such forward-looking statements involve risks and uncertainties including, without limitation, unforeseen changes in the course of research and development activities and in clinical trials; the uncertainties of and difficulties in analyzing interim clinical data; the significant expense, time, and risk of failure of conducting clinical trials; the need for Celsion to evaluate its future development plans; possible acquisitions or licenses of other technologies, assets or businesses; possible actions by customers, suppliers, competitors, regulatory authorities; and other risks detailed from time to time in Celsion's periodic reports and prospectuses filed with the Securities and Exchange Commission. Celsion assumes no obligation to update or supplement forward-looking statements that become untrue because of subsequent events, new information or otherwise.
Celsion Investor Contact
Jeffrey W. Church
Executive Vice President and CFO
609-482-2455
jchurch@celsion.com
####
FAQ
What is the date of Celsion's presentation at the H.C. Wainwright conference?
Who is presenting for Celsion at the H.C. Wainwright conference?
Where is the H.C. Wainwright 24th Annual Global Investment Conference being held?
What can investors expect from the Celsion presentation?
Is there a way to access Celsion's presentation after it concludes?
